Details for New Drug Application (NDA): 070265
✉ Email this page to a colleague
NDA 070265 describes METHYLDOPA AND HYDROCHLOROTHIAZIDE, which is a drug marketed by Chartwell Rx, Dava Pharms Inc, Ivax Sub Teva Pharms, Parke Davis, Purepac Pharm, Rising, Sandoz, Strides Pharma, Teva, and Watson Labs, and is included in forty-three NDAs. Additional details are available on the METHYLDOPA AND HYDROCHLOROTHIAZIDE profile page.
The generic ingredient in METHYLDOPA AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; methyldopa. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; methyldopa profile page.
The generic ingredient in METHYLDOPA AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; methyldopa. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; methyldopa profile page.
Summary for 070265
| Tradename: | METHYLDOPA AND HYDROCHLOROTHIAZIDE |
| Applicant: | Rising |
| Ingredient: | hydrochlorothiazide; methyldopa |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG;250MG | ||||
| Approval Date: | Jan 23, 1986 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 15MG;250MG | ||||
| Approval Date: | Jan 23, 1986 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
